Ip Share Discussion Threads

[hashertu] 24/3/2021 11:05

Bamboo2. Interesting. Huge market if they can make it a commercial success.

[hashertu] 23/3/2021 10:44

You can always trust the tea leaves.
I wonder if ONT and AGL have much interaction?

[bamboo2] 23/3/2021 08:29

hashertu, with IPO there's plenty to choose from!

Re ONT/Cancer diagnostics, I am anticipating an announcement of some kind later this week.

[hashertu] 22/3/2021 11:20

Bamboo2. That the catalyst is unknown is what makes it interesting for me personally.
I am enjoying the journey.

[bamboo2] 20/3/2021 17:30

scuba, thanks for the article.

It's behind a paywall, but if you google it, then, without accepting cookies, select the cached text option, it can be accessed.

Hard to believe, but the premium here in the earlier days of Woodford was nearly 100%.

I'm not sure we will ever return to that level. We are currently trading at a slight discount to nav [approx 125].

Given the fact that recently many tech companies SP's have been in retreat, and that IPGroup has had a great year for cashing out, it is hard to see where the catalyst for further advancement here will come.

We do know the Gordon Sanghera has suggested the value of ONT will double year on year for the next four years. If this was the case at the end of the year, ONT could add around 32p to the IPGroup share price.

[scubadiverr] 19/3/2021 11:57

https://www.investorschronicle.co.uk/ideas/2021/03/18/ip-group-premium-could-soon-return/

[hashertu] 19/3/2021 11:45

bamboo2.
I think you are right. The snippet I read from the IPO search engine was in the context of OSI.
This is why I looked.

[bamboo2] 18/3/2021 15:02

hashertu, IPO have a small amount of OSI [2.3%]

OSI has holdings in Vaccitech.

The subject of OSI came up in the Q&A during the presentation.
I have an idea that IPO was one of the founders of OSI.
The holding has been reduced as IPGroup management expect to become co-investors with OSI in spinouts from the University, either directly and/or with Parkwalk.

As far as I know there is no direct holding in Vaccitech.

[bamboo2] 18/3/2021 14:42

Possible turn showing on my chart today.
Assuming it materialises and confirms it can, at present, only be a high or peak turn.

[hashertu] 17/3/2021 12:28

Do IPO still have a shareholding in Vaccitech?
I can find a £20m investment in 2017 but don't know what has happened since.

[hashertu] 17/3/2021 12:07

Apologies if old news.
I am sometimes late to the party.
I noted a reference to Nanopore on the KMK BB.
This might be the connection.
I think I looked at KMK after seeing a ST tip in the IC.



Abstract from Innovate UK

Next he discussed how this technology could be translated into agriculture. The Air-Seq project, in collaboration with Matt Clark at the Natural History Museum, examined the use of nanopore sequencing techniques to detect plant disease spores in the air. Located next to trial plots of wheat and barley, this tool identified spores of key diseases such as yellow rust (Puccinia striiformis) and barley powdery mildew (Blumeria graminis f. share price Hordei), with good correlation to disease development in the nearby crop. This project is now being built upon with the help of Kromek Plc and a PhD studentship funded by DARPA, but he hopes to develop an autonomous early detection network across the UK.

hxxps://chap-solutions.co.uk/news/ei-innovate-2020-examines-disease-monitoring-and-detection/

[wetpantz] 15/3/2021 17:09

Anyone got info or views on Waveoptics? another IPO portfolio company that could hit it big globally, says working with several top tier tech companies but sworn to secrecy. I dunno how its AR lenses compare with the competition, hard to find much info out there.

[hashertu] 15/3/2021 12:32

Is it just my imagination, or has the ONT website had a significant make-over?

[bamboo2] 13/3/2021 09:21

Pulmocide Ltd. IPGroup own 17.6%

11 Mar 2021

Pulmocide Ltd., which is developing first-in-class inhaled anti-infectives for targeted treatment of life-threatening lung infections, today announces the publication of two papers in key scientific journals featuring Pulmocide’s lead drug candidate, PC945.
PC945 is the first triazole antifungal specifically designed for delivery to the lung via inhalation and is currently being developed for the treatment of invasive pulmonary Aspergillus disease, a potentially life-threatening complication in immunocompromised patients.

The first paper, published in the Journal of Heart and Lung Transplantation, outlines case studies of two patients who underwent a lung transplant and subsequently developed serious, life-threatening Aspergillus infection at the anastomotic site (where the patient’s airways join the airway of the donor lung). In both patients the disease had continued to progress despite months of treatment with a series of approved antifungals. The paper, entitled Successful salvage therapy for fungal bronchial anastomotic infection after lung transplantation with an inhaled triazole anti-fungal PC945, describes the rapid and complete resolution of the infection in both patients after nebulized PC945 was commenced.

The full publication is available online and can be viewed here:


Dr Lance Berman, Chief Medical Officer of Pulmocide, commented: “Aspergillus infection is a devastating complication of lung transplantation which can lead to increased morbidity and mortality, and often these infections do not respond to current treatment options. Following inhaled delivery of PC945, the two patients highlighted in this paper showed complete resolution of the infection within three months indicating the potential of PC945 as a treatment option for Aspergillus infections. We look forward to progressing PC945 to Phase 3 later this year.”

The second paper, Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent, published in Pharmaceutical Research and Perspectives, reports data on the pharmacokinetic and safety profiles from nonclinical studies including the low potential for drug-drug interactions, and a Phase 1 clinical trial in healthy subjects and subjects with mild asthma following nebulised delivery of PC945.

The data show that PC945 was well-tolerated, and findings from clinical and nonclinical studies demonstrated that repeat daily doses of inhaled PC945 led to prolonged retention in the lung with minimal systemic exposure, limiting the potential for adverse events and drug interactions commonly seen with systemically delivered azoles. These data suggest that inhaled PC945 could have a much wider therapeutic index than systemic antifungal agents.

Dr Pete Strong, Chief Scientific Officer of Pulmocide, commented: “The Phase 1 study and non-clinical data described in the Pharmaceutical Research and Perspectives publication represents an important step in the characterisation of PC945 in lung tissue and systemic circulation and enables us to proceed into later stage clinical trials with confidence. We are excited to start our Phase 3 program this year and look forward to updating the scientific community on clinical progress in due course.”

The full publication is available online and can be viewed here:

A Phase 3 program with PC945 is expected to start this year to assess the drug candidate in the treatment of second-line, invasive pulmonary Aspergillus disease as part of a combined anti-fungal regimen. The program will also evaluate the safety and pharmacokinetics of the drug when used as monotherapy in preventing Aspergillus disease in lung transplant patients.

About Pulmonary Aspergillosis
The incidence of pulmonary fungal infections has increased substantially over the past two decades; Aspergillus species being the most common of these. Invasive pulmonary aspergillosis is associated with a high mortality and morbidity in immuno-compromised patients, for example, those undergoing haematological stem cell or solid organ transplantation, (particularly lung transplants) and some patients in critical care. Aspergillus infection also plays an important role in severe asthma and cystic fibrosis and has been correlated with poorer clinical outcome in patients with chronic obstructive pulmonary disease. Chronic lung infections with Aspergillus can leave patients with extensive and permanent lung damage, requiring lifetime antifungal treatment.

About PC945
PC945 is a novel inhaled triazole antifungal agent which is being developed to treat or prevent pulmonary fungal disease. PC945 has been specifically designed for inhalation. Its characteristics enable high lung absorption and retention, with minimal uptake into the systemic circulation. This ensures the delivery of a high concentration of the drug directly to the site of infection while minimizing the potential for systemic toxicities and drug interactions. The profile of PC945 has been assessed in a range of in vitro and in vivo studies in which it has been demonstrated to have potent antifungal activity against Aspergillus and Candida species and a range of other fungi. Available clinical data thus far indicate that PC945 is well tolerated and that systemic drug concentrations are extremely low.

About Pulmocide
Pulmocide Ltd ( is a clinical-stage biopharmaceutical company focused on the development of novel inhaled therapies for life-threatening lung infections. Our lead program, PC945, is a novel, inhaled, antifungal agent for the management of pulmonary fungal diseases which has the potential to address multiple indications. In 2021 we anticipate initiating a Phase 3 clinical trial for the treatment of second-line, invasive pulmonary Aspergillus disease as part of a combined antifungal regimen. The company is also considering the potential of PC945 to prevent pulmonary fungal disease in at-risk patients and as a treatment for chronic Aspergillus infections.

[podgyted] 12/3/2021 07:50

* IP Group Plc IPO.L : Berenberg raises target price to 148p from 138p

[robertspc1] 10/3/2021 18:19

I think they have another unicorn possibility in Oxbotica. Leading player in autonomous vehicle software... not just cars which will take a while but industrial vehicles etc

[bamboo2] 10/3/2021 15:54

Pierre, I would guess that after the ONT flotation, IPGroup would keep their holding at 15% meaning that there would not be cash for a handout from this source. The share price would subsequently be set by the market and we would have the opportunity to buy shares directly.

I thought the call was interesting although they didn't really get to the nub of the issue about the missing millions of shares, we are talking about over 25% of the company.

I have also had a separate email reply, but that doesn't help either. Aubrey did say that they were not aware of any stake building.

Good to see the co show a profit, and good to see the regular dividend.

ps. I just remembered that Alan Aubrey did give away something about the significant shareholders situation. He said some of the existing holders had added 'a bit'. That must mean he at least recognises the fact of the matter.

[robertspc1] 10/3/2021 10:38

Good positive investor call. ONT going great guns and very well positioned etc etc. Anyone know off hand what their year end is ?

[p1nkfish] 10/3/2021 08:53

Buyback, not divi. More tax efficient and still positively impacts shareholder return. IPO also need big cash balance for support and new investments.

[pierre oreilly] 10/3/2021 08:24

Given IPO are at last looking slightly progressive - if paying an obvious Divi can be described as that - perhaps the board could cement their progressive outlook to reflect the larger than necessary cash balance surplus to any sensible new investment needs and come out to explicitly state they intend to return all the proceeds from a nano float to shareholders as a special Divi.Any comment this time pink?

[pierre oreilly] 10/3/2021 08:16

Well I never, a 1p Divi.Whenever I suggested a Divi istr pink at my neck telling me to invest in a Divi paying share and not IPO, at incidentally a price 30% less than today.The path is now clear for substantial share price gains - the cash they have can fund an increasing Divi for yonks while still having a big surplus over their seed investment needs.

[masurenguy] 10/3/2021 07:45

Excellent set of results and positive prospects for 2021 ! 😊

IP Group plc Annual Results Release

Record returns and cash realisations, strong financial position, maiden dividend.

IP Group plc (LSE: IPO), the developer of intellectual property-based businesses, today announces its annual financial results for the year ended 31 December 2020.

Portfolio highlights

-- Strong growth, realisations and ongoing investment
o Fair value of portfolio: GBP1,162.7m (2019: GBP1,045.6m)
o Net portfolio gains of GBP231.4m or approximately +22%(1) (2019: reduction of GBP43.9m)
o 140% increase in cash realisations (2) to GBP191.0m (2019: GBP79.5m)
o Sustained investment into portfolio: GBP67.5m (2019: GBP64.7m)

-- Proving the model - from investment to exit
o Total funds raised by portfolio companies GBP1.1bn (2019: GBP430m) including Oxford Nanopore (GBP162.1m), Hinge Health ($392m), Oxbotica (GBP27m), MobilION (GBP40m), Featurespace (GBP30m), Inivata ($25m).
o Exited Ceres Power for GBP128m at seven times cost

-- 20 years of impact investing - supporting world-changing businesses
o Portfolio has created three 'unicorns': Oxford Nanopore, Ceres Power, Hinge Health
o A number of our portfolio companies, most notably Oxford Nanopore, are actively involved in the response to COVID-19
o Appointment of Prof. Gordon Clark as Chair of ESG Ethics Committee

Financial and operational highlights

-- Hard NAV(3) GBP1,331.5m or 125.3 pence per share (2019: GBP1,141.5m or 107.8 pence per share)

-- Net assets GBP1,331.9m (2019: GBP1,141.9m)
-- Profit of GBP185.4m (2019: loss of GBP78.9m)
-- Record positive Return on Hard NAV(3) of GBP189.5m or 17% (2019: -73.7m or -6%)
-- Strong liquidity with gross cash and deposits at 31 December 2020 of GBP270.3m (2019: GBP194.9m) and net cash (gross cash and deposits less EIB debt) of GBP203.0m (2019: GBP112.4m)
-- Recommended maiden dividend of 1pps, including scrip alternative

Post period-end update

-- North American platform, IP Group, Inc., secured an additional $50.0m (GBP36.5m*) of funding, including $40.0m from a new US blue-chip institutional investor alongside $10m from IP Group.
(1) 23% return on opening portfolio value of GBP1,045.6m
(2) Proceeds from sale of equity and debt investments per Group Cash Flow Statement
(3) Alternative performance measure, see note 29 for definition and reconciliation to IFRS primary statements

Alan Aubrey, Chief Executive of IP Group, said: "IP Group made excellent progress in 2020, achieving both record returns and cash realisations totalling GBP191m. This financial strength, combined with the prospects in our maturing portfolio, gives us the confidence to recommend a maiden dividend of 1 pence per share. We have great pride in the contribution of many of our companies to the response to COVID-19. The pandemic has focused attention on the importance of innovation of science, accelerating key thematic trends in health, digitisation, and the transition to net zero. We remain confident that IP Group is well positioned to benefit from both the increased focus and these thematic trends. This year, as IP Group celebrates 20 years of generating innovation, we are excited about the prospects for the portfolio as well as the impact the Group can have from the renewed focus on innovation and sustainability. The current year has started strongly, with much activity in the portfolio including significant fundraisings, and we remain excited by the prospects for 2021."

[stephan14] 09/3/2021 18:09

Update on Oxford Nanopore. When will they go public ?

[zandy92] 09/3/2021 17:37

Any thoughts on tomorrow ???